Meeting
2021 ASCO Annual Meeting
The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
Authors
Nour Abuhadra
MD Anderson Hematology/Oncology Fellowship, Houston, TX
Nour Abuhadra , Chia-Chi Chang , Clinton Yam , Jason B White , Elizabeth Ravenberg , Bora Lim , Naoto T. Ueno , Jennifer Keating Litton , Banu Arun , Senthil Damodaran , Rashmi Krishna Murthy , Nuhad K. Ibrahim , Gabriel N. Hortobagyi , Vicente Valero , Debu Tripathy , Alastair Mark Thompson , Elizabeth A. Mittendorf , Lei Huo , Stacy L. Moulder , Robert R. Jenq
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 590)
DOI
10.1200/JCO.2021.39.15_suppl.590
Abstract #
590
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443).
First Author: Sahil Seth
Poster
2017 ASCO Annual Meeting
Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).
First Author: Charles E. Geyer Jr.
Poster
2014 ASCO Annual Meeting
Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).
First Author: Gunter Von Minckwitz
Poster
2021 ASCO Annual Meeting
ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.
First Author: Shigehira Saji